Payment overview · 2025
General Payments
$2,295.01
71 reported records · 13 companies
Healthcare provider profile · identity verified
Michael C. Liou, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · NEW YORK, NY · NPI 1447456231
Verified facts
What the public records show
CMS Open Payments records show Michael C. Liou, M.D. received $2,295.01 in general payments during 2025 across 71 reported records.
Boston Scientific Corporation accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Nexletol, Rybelsus, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 279 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1084 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexlizet by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 479 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $403.51 | 17.6% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $326.12 | 14.2% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $305.59 | 13.3% | 13 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $251.40 | 10.9% | 12 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $189.99 | 8.3% | 14 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $188.18 | 8.2% | 1 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $170.76 | 7.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $140.91 | 6.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$110.96 | 4.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $82.02 | 3.6% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $66.05 | 2.9% | 3 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $32.95 | 1.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.57 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,295.01 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $326.12 | 15 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $300.11 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $251.40 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $199.36 | 8 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $188.18 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $188.18 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $170.76 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $140.91 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $110.96 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $105.54 | 8 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $98.76 | 5 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $84.45 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $82.02 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $66.05 | 3 | 2025 |
Source payment records
|
|||||
| 2cm Peripheral Cutting Balloon Normalized: 2cm peripheral cutting balloon |
Device | Boston Scientific Corporation | $54.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $49.20 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $39.22 | 1 | 2025 |
Source payment records
|
|||||
| Venclose Maven Catheter Normalized: venclose maven catheter |
Device | Bard Peripheral Vascular, Inc. | $32.95 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $31.25 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $9.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1084 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 479 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 269 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 279 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
139 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
269 | 76 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
279 | 60 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1084 | 196 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
479 | 83 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 2588 | 555 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1793 | 447 |
| Xarelto | Rivaroxaban | 1537 | 269 |
| Nitroglycerin | Nitroglycerin | 1526 | 389 |
| Amlodipine Besylate | Amlodipine Besylate | 1191 | 281 |
| Vascepa | Icosapent Ethyl | 1128 | 221 |
| Eliquis | Apixaban | 1084 | 196 |
| Losartan Potassium | Losartan Potassium | 967 | 246 |
| Clopidogrel | Clopidogrel Bisulfate | 880 | 219 |
| Ranolazine Er | Ranolazine | 655 | 123 |
| Gabapentin | Gabapentin | 588 | 125 |
| Carvedilol | Carvedilol | 548 | 118 |
| Entresto | Sacubitril/Valsartan | 479 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 446 | 128 |
| Furosemide | Furosemide | 416 | 124 |
| Diclofenac Epolamine | Diclofenac Epolamine | 377 | 63 |
| Diclofenac Sodium | Diclofenac Sodium | 369 | 101 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 357 | 71 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 355 | 89 |
| Meloxicam | Meloxicam | 315 | 81 |
| Hydralazine Hcl | Hydralazine Hcl | 302 | 68 |
| Jardiance | Empagliflozin | 279 | 60 |
| Meclizine Hcl | Meclizine Hcl | 278 | 77 |
| Farxiga | Dapagliflozin Propanediol | 269 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 68 |
| Omeprazole | Omeprazole | 225 | 56 |
| Ezetimibe | Ezetimibe | 220 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 213 | 61 |
| Propranolol Hcl | Propranolol Hcl | 210 | 46 |
| Atenolol | Atenolol | 206 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 197 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 179 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 169 | 37 |
| Nebivolol Hcl | Nebivolol Hcl | 155 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 145 | 44 |
| Dexlansoprazole Dr | Dexlansoprazole | 140 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 42 |
| Brilinta | Ticagrelor | 139 | 26 |
| Simvastatin | Simvastatin | 128 | 37 |
| Digoxin | Digoxin | 125 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 125 | 31 |
| Spironolactone | Spironolactone | 124 | 35 |
| Multaq | Dronedarone Hcl | 121 | 24 |
| Lisinopril | Lisinopril | 115 | 27 |
| Warfarin Sodium | Warfarin Sodium | 112 | 20 |
| Montelukast Sodium | Montelukast Sodium | 109 | 27 |
| Metformin Hcl Er | Metformin Hcl | 103 | 24 |
| Nifedipine Er | Nifedipine | 91 | 23 |
| Hydrocortisone | Hydrocortisone | 87 | 20 |
| Ammonium Lactate | Ammonium Lactate | 83 | 18 |
| Colchicine | Colchicine | 72 | 16 |
| Potassium Chloride | Potassium Chloride | 72 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 20 |
| Sucralfate | Sucralfate | 67 | suppressed |
| Finasteride | Finasteride | 65 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 23 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 60 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 60 | 13 |
| Januvia | Sitagliptin Phosphate | 60 | 14 |
| Valsartan | Valsartan | 60 | 15 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 58 | suppressed |
| Metformin Hcl | Metformin Hcl | 57 | 20 |
| Icosapent Ethyl | Icosapent Ethyl | 56 | 24 |
| Diltiazem Hcl | Diltiazem Hcl | 54 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 54 | suppressed |
| Repatha Sureclick | Evolocumab | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 14 |
| Levothyroxine Sodium | Levothyroxine Sodium | 44 | 11 |
| Famotidine | Famotidine | 43 | 15 |
| Telmisartan | Telmisartan | 43 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 41 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 39 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 39 | 20 |
| Glipizide Er | Glipizide | 39 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 37 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 19 |
| Xiidra | Lifitegrast | 34 | suppressed |
| Lactulose | Lactulose | 32 | suppressed |
| Nexium | Esomeprazole Magnesium | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Praluent Pen | Alirocumab | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | 15 |
| Fenofibrate | Fenofibrate,micronized | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 28 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Livalo | Pitavastatin Calcium | 25 | suppressed |
| Verquvo | Vericiguat | 25 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Edarbi | Azilsartan Medoxomil | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 15 | suppressed |
| Dexilant | Dexlansoprazole | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Nexletol | Bempedoic Acid | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Bystolic | Nebivolol Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Cephalexin | Cephalexin | 12 | 12 |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,295.01 · 71 records | Boston Scientific Corporation | 2cm Peripheral Cutting Balloon, AVEIR, AVVIGO Guidance System, BIOMONITOR, CAMZYOS, CAPVAXIVE, Cleerly Ischemia, Cleerly Labs, ELIQUIS, ENTRESTO, FARXIGA, General - Therapies, INTERSTIM, JARDIANCE, LEQVIO, LOKELMA, NEXLETOL, Ozempic, Rybelsus, VERQUVO, Venclose Maven Catheter, WATCHMAN Access System | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error